Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Silke Hobbie

Christoph Hoenke

Matthias Hoffmann

Annette Schuler-Metz

Andreas Schnapp

Riccardo Giovannini

Stefan Peters

Sandra Handschuh

Dennis Fiegen

Heiner Ebel

Takeshi Kono

Yayoi Sato

Sara Frattini

Thierry Bouyssou

Domnic Martyres

Stefan Scheuerer

Thomas Trieselmann

Pascale Pouzet

Frank Buettner

Peter Seither

Patrick Tielmann

The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein

4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments

The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.

Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD

CCR2 receptor antagonists and uses thereof

The invention relates to novel substituted naphthyridines of formula 1 as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates, or solvates thereof. In formula 1, Rcan represent a group A selected from among the group comprising &#x2014;O&#x2014;R, &#x2014;NRR, &#x2014;CRRR, -(ethyne)-R, &#x2014;S&#x2014;R, &#x2014;SO&#x2014;R, and SO&#x2014;R, or Rrepresents a group B selected from among the group comprising: &#x2014;C-aryl; &#x2014;a five-membered to ten-membered, monocyclic or bicyclic heteroaryl containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heteroaryl is linked to the structure according to formula 1 via a C atom or an N atom; &#x2014;a three-membered to ten-membered, monocyclic or bicyclic, saturated or partially saturated heterocycle containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heterocycle is linked to the structure according to formula 1 via a C atom or an N atom; and &#x2014;a 5-membered to 11-membered spiro group which can optionally contain 1, 2, or 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said spiro group is linked to the structure according to formula 1 via a C atom or an N atom, wherein said group B can be optionally substituted as described in claims, and R, R, R, R, and m can have the meanings indicated in claim. The invention also relates to pharmaceutical compositions containing said compounds. 

Disclosed are novel piperidine-substituted indoles- or heteroderivatives thereof of the formula 1: wherein R, R, R, R, A, B, D-E, Y, i, j, n and m are defined as below. The compounds of formula 1 are useful as agonists or antagonists of CCR-3. The present invention is also directed to pharmaceutically acceptable salts thereof, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.

Piperidine-substituted indoles

Growing community of inventors

Biberach an der Riss, Germany

Silke Hobbie